NAZ2329, the first cell-permeable inhibitor of R5 subfamily of receptor-type protein tyrosine phosphatases (RPTPs), allosterically and preferentially inhibits PTPRZ (IC₅₀=7.5 μM for hPTPRZ1) and PTPRG (IC₅₀=4.8 μM for hPTPRG) over other PTPs. NAZ2329 binds to the active D1 domain and more potently inhibits PTPRZ-D1 fragment (IC₅₀ of 1.1 μM) than the whole intracellular (D1?+?D2) fragment (IC₅₀ of 7.5 μM). NAZ2329 can effectively inhibit tumor growth of the glioblastoma cells and suppress stem cell-like properties^[1] .

IC50: 7.5 μM (PTPRZ), 4.8 μM (PTPRG), 35.7 μM (PTPRA), 56.7 μM (PTPRM), 23.7 μM (PTPRS), 35.4 μM (PTPRB), 15.2 μM (PTPN6), 14.5 μM (PTPN1)^[1]

NAZ2329 (0-25 μM; 48 hours) dose-dependently inhibits cell proliferation and migration in all cell lines (rat glioblastoma cells bearing C6 clone and human U251 glioblastoma cells) ^[1] .
NAZ2329 (25 μM; 0-90 min) obviously promotes the phosphorylation level of paxillin at Tyr-118 site, leading to inhibition for PTPR substrate^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

NAZ2329 (22.5 mg/kg; intraperitoneal injection; twice per week; 40 days) alone has a moderate inhibitory effect. However, the combination of Temozolomide and NAZ2329 exerts a significantly increased inhibition of tumor growth compared with the control group, the NAZ2329 monotherapy group and the Temozolomide monotherapy group^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

501.56

C??H??F?NO?S?

CCOC1=C(CSC2=C(C(NS(=O)(C3=CC=CC=C3)=O)=O)SC=C2)C=C(C(F)(F)F)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Akihiro Fujikawa, et al. Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells. Sci Rep. 2017 Jul 17;7(1):5609.